



**DukeHeart** *On The Go*

# Results from the EMPULSE Trial: Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized For Acute Heart Failure

Mikhail Kosiborod, MD, FACC, FAHA  
Professor of Medicine  
Saint Luke's Mid America Heart Institute  
Kansas City, MO, USA

Mikhail Kosiborod,<sup>1,2</sup> Christiane E. Angermann,<sup>3</sup> Sean Collins,<sup>4</sup> John R. Teerlink,<sup>5</sup> Piotr Ponikowski,<sup>6</sup> Jan Biegus,<sup>6</sup> Josep Comin-Colet,<sup>7</sup> João Pedro Ferreira,<sup>8,9</sup> Robert Mentz,<sup>10</sup> Michael E. Nassif,<sup>1</sup> Mitchell Psozka,<sup>11</sup> Jasper Tromp,<sup>12</sup> Martina Brueckmann,<sup>13,14</sup> Jonathan Blatchford,<sup>15</sup> Afshin Salsali,<sup>16,17</sup> Adriaan A. Voors<sup>18</sup>

<sup>1</sup>Saint Luke's Mid America Heart Institute and the University of Missouri, Kansas City, MO, USA; <sup>2</sup>George Institute for Global Health and the University of New South Wales, Sydney, NSW, Australia; <sup>3</sup>Comprehensive Heart Failure Centre, University & University Hospital of Würzburg, Würzburg, Germany; <sup>4</sup>Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; <sup>5</sup>Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, CA, USA; <sup>6</sup>Institute of Heart Diseases, Medical University, Wrocław, Poland; <sup>7</sup>Hospital Universitario de Bellvitge, Barcelona, Spain; <sup>8</sup>Université de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France; <sup>9</sup>Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; <sup>10</sup>Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC, USA; <sup>11</sup>Inova Heart and Vascular Institute, Falls Church, VA, USA; <sup>12</sup>Saw Swee Hock School of Public Health, National University of Singapore, Singapore; <sup>13</sup>Boehringer Ingelheim International GmbH, Ingelheim, Germany; <sup>14</sup>Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany; <sup>15</sup>Elderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; <sup>16</sup>Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; <sup>17</sup>Faculty of Medicine, Rutgers University, New Brunswick, NJ, USA; <sup>18</sup>University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands




# Background

- Patients hospitalized for acute heart failure (AHF) experience poor health status, including high burden of symptoms and physical limitations as well as poor quality of life
- Improving health status is a key goal of management
- To date, there has been a lack of therapies with compelling benefit for these outcomes in AHF, highlighting a critical unmet need
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve health status in chronic heart failure, but their effects in AHF have not been well characterized


# Objectives of This EMPULSE Analysis

- Evaluate the effects of empagliflozin on the primary endpoint of total clinical benefit in the EMPULSE trial according to the degree of symptomatic impairment at baseline
- Examine the impact of empagliflozin on the broad range of health status outcomes, as measured by various domains of the Kansas City Cardiomyopathy Questionnaire (KCCQ), and the time course of these effects

# Effects of Empagliflozin Versus Placebo on the Primary Hierarchical Composite Endpoint of Clinical Benefit Across Tertiles of KCCQ-TSS



# Effects of Empagliflozin Versus Placebo on Change in KCCQ-TSS



N with data at visit

Placebo

250

240

234

221

Empagliflozin


245

233


237

230


# Effects of Empagliflozin Versus Placebo on Change in KCCQ-OSS, -CSS, -PLS and -QoL




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230



N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230




N with data at visit				
Placebo	245	232	225	217
Empagliflozin	240	225	228	225




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230


# Effects of Empagliflozin Versus Placebo on Change in KCCQ-OSS, -CSS, -PLS and -QoL




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230



N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230




N with data at visit				
Placebo	245	232	225	217
Empagliflozin	240	225	228	225




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230


# Effects of Empagliflozin Versus Placebo on Change in KCCQ-OSS, -CSS, -PLS and -QoL




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230



N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230




N with data at visit				
Placebo	245	232	225	217
Empagliflozin	240	225	228	225




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230




# Effects of Empagliflozin Versus Placebo on Change in KCCQ-OSS, -CSS, -PLS and -QoL




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230



N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230




N with data at visit				
Placebo	245	232	225	217
Empagliflozin	240	225	228	225




N with data at visit				
Placebo	250	240	234	221
Empagliflozin	245	233	237	230

# Effects of Empagliflozin Versus Placebo on Change in KCCQ-OSS, -CSS, -PLS and -QoL




N with data at visit

	Baseline	Day 15	Day 30	Day 90
Placebo	250	240	234	221
Empagliflozin	245	233	237	230




N with data at visit

	Baseline	Day 15	Day 30	Day 90
Placebo	250	240	234	221
Empagliflozin	245	233	237	230



N with data at visit

	Baseline	Day 15	Day 30	Day 90
Placebo	245	232	225	217
Empagliflozin	240	225	228	225



N with data at visit

	Baseline	Day 15	Day 30	Day 90
Placebo	250	240	234	221
Empagliflozin	245	233	237	230

# Conclusions

- Treatment with empagliflozin produced total clinical benefit across the entire range of KCCQ among patients hospitalized with AHF
  - Indicates that the benefits of empagliflozin in this patient group are independent of symptomatic impairment at baseline
- Empagliflozin significantly improved all key KCCQ domains (which collectively encompass symptoms, physical function, quality of life, and social function)
- Benefits seen as early as 15 days, and maintained through 90 days

# Circulation

CIRCULATION. 2022; [PUBLISHED ONLINE AHEAD OF PRINT]. DOI: 10.1161/CIRCULATIONAHA.122.059725

## EFFECTS OF EMPAGLIFLOZIN ON SYMPTOMS, PHYSICAL LIMITATIONS AND QUALITY OF LIFE IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE – RESULTS FROM THE EMPULSE TRIAL

MIKHAIL N. KOSIBOROD, MD; CHRISTIANE E. ANGERMANN, MD; SEAN P. COLLINS, MD, MSC;  
JOHN R. TEERLINK, MD; PIOTR PONIKOWSKI, MD, PHD; JAN BIEGUS, MD, PHD; JOSEP COMIN-  
COLET, MD, PHD; JOÃO PEDRO FERREIRA, MD, PHD; ROBERT J. MENTZ, MD; MICHAEL E. NASSIF,  
MD; MITCHELL A. PSOTKA, MD, PHD; JASPER TROMP, MD, PHD; MARTINA BRUECKMANN, MD;  
JONATHAN P. BLATCHFORD, CSTAT; AFSHIN SALSALI, MD; ADRIAAN A. VOORS, MD, PHD

***CIRCULATION***

[HTTPS://WWW.AHAJOURNALS.ORG/DOI/10.1161/CIRCULATIONAHA.122.059725](https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059725)